The T Cell-mediated Tumor Killing Patterns Revealed Tumor Heterogeneous and Proposed Treatment Recommendation in Ovary Cancer

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2024 Dec 5

PMID 39638927

Authors

Xinglin Wen

Beining Yin

Li Lin

Long Liu

Siyuan Weng

Hui Xu

Yuyuan Zhang

Jinhai Deng

Ruiying Liao

Cungeng Fan

Affiliations

Soon will be listed here.

Abstract

Background: Immune checkpoint inhibitors (ICIs) have greatly improved cancer treatment, but the role of genes related to T cell-mediated tumor killing (TTK) sensitivity in ovarian cancer (OV) is unclear.

Methods: This study analyzed 1367 OV patients and 11 independent cohorts. The unsupervised clustering was conducted to identify three tumor subtypes based on genes that regulate tumor cell sensitivity to TTK (GSTTKs). The biological characteristics, genetic variations, immunological landscape, and therapeutic evaluation for each subtype were further explored.

Results: Patients were divided into three reproducible subtypes based on 61 GSTKKs associated with prognosis. C1 was likely to be an invasive subtype with the worst prognosis and highly unstable genome. C2 might be an immune-active subtype with the best prognosis, high immune infiltration and preferable response to immunotherapy. C3 might be a metabolic subtype, resistant to immunotherapy, but sensitive to drug therapy. Following an extensive exploration into a variety of distinct molecular features between the three subtypes, the results suggested that C2 patients were considered to derive significant efficacy from immunotherapy. For C1 and C3 patients, chemotherapy might be an ideal treatment strategy.

Conclusions: In this study, three GSTKKs-based subtypes were identified by assessing TTK patterns in OV. These new insights further improved our understanding of GSTTKs and might refine clinical treatment strategies for OV patients.

References

Yang Z, Wang W, Zhao L, Wang X, Gimple R, Xu L . Plasma cells shape the mesenchymal identity of ovarian cancers through transfer of exosome-derived microRNAs. Sci Adv. 2021; 7(9). PMC: 7904265. DOI: 10.1126/sciadv.abb0737. View

Baci D, Bosi A, Gallazzi M, Rizzi M, Noonan D, Poggi A . The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors. Int J Mol Sci. 2020; 21(9). PMC: 7247443. DOI: 10.3390/ijms21093125. View

Zhao B, Zhao H, Zhao J . Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. Ther Adv Med Oncol. 2020; 12:1758835920937612. PMC: 7366397. DOI: 10.1177/1758835920937612. View

Luengo A, Gui D, Vander Heiden M . Targeting Metabolism for Cancer Therapy. Cell Chem Biol. 2017; 24(9):1161-1180. PMC: 5744685. DOI: 10.1016/j.chembiol.2017.08.028. View

Lim H, Merle P, Weiss K, Yau T, Ross P, Mazzaferro V . Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with -Mutated Hepatocellular Carcinoma. Clin Cancer Res. 2018; 24(19):4650-4661. DOI: 10.1158/1078-0432.CCR-17-3588. View

Ru B, Wong C, Tong Y, Zhong J, Zhong S, Wu W . TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019; 35(20):4200-4202. DOI: 10.1093/bioinformatics/btz210. View

Peter S, Alven S, Maseko R, Aderibigbe B . Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review. Molecules. 2022; 27(14). PMC: 9318127. DOI: 10.3390/molecules27144478. View

Saani I, Raj N, Sood R, Ansari S, Mandviwala H, Sanchez E . Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours. Int J Environ Res Public Health. 2023; 20(12). PMC: 10298722. DOI: 10.3390/ijerph20126089. View

Lheureux S, Braunstein M, Oza A . Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019; 69(4):280-304. DOI: 10.3322/caac.21559. View

10.

Herrera M, Berral-Gonzalez A, Lopez-Cade I, Galindo-Pumarino C, Bueno-Fortes S, Martin-Merino M . Cancer-associated fibroblast-derived gene signatures determine prognosis in colon cancer patients. Mol Cancer. 2021; 20(1):73. PMC: 8082938. DOI: 10.1186/s12943-021-01367-x. View

11.

Wang X, Duanmu J, Fu X, Li T, Jiang Q . Analyzing and validating the prognostic value and mechanism of colon cancer immune microenvironment. J Transl Med. 2020; 18(1):324. PMC: 7456375. DOI: 10.1186/s12967-020-02491-w. View

12.

Millstein J, Budden T, Goode E, Anglesio M, Talhouk A, Intermaggio M . Prognostic gene expression signature for high-grade serous ovarian cancer. Ann Oncol. 2020; 31(9):1240-1250. PMC: 7484370. DOI: 10.1016/j.annonc.2020.05.019. View

13.

Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay R, Luoma A . A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018; 359(6377):770-775. PMC: 5953516. DOI: 10.1126/science.aao1710. View

14.

Zhang N, Bevan M . CD8(+) T cells: foot soldiers of the immune system. Immunity. 2011; 35(2):161-8. PMC: 3303224. DOI: 10.1016/j.immuni.2011.07.010. View

15.

Aliyuda F, Moschetta M, Ghose A, Rallis K, Sheriff M, Sanchez E . Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors. Curr Cancer Drug Targets. 2023; 23(6):433-446. DOI: 10.2174/1568009623666230209121732. View

16.

Yi Q, Pu Y, Chao F, Bian P, Lv L . ACAP1 Deficiency Predicts Inferior Immunotherapy Response in Solid Tumors. Cancers (Basel). 2022; 14(23). PMC: 9740925. DOI: 10.3390/cancers14235951. View

17.

Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

18.

Odunsi K . Immunotherapy in ovarian cancer. Ann Oncol. 2017; 28(suppl_8):viii1-viii7. PMC: 5834124. DOI: 10.1093/annonc/mdx444. View

19.

Pavlidis N, Rassy E, Vermorken J, Assi T, Kattan J, Boussios S . The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. Cancer Epidemiol. 2021; 75:102045. DOI: 10.1016/j.canep.2021.102045. View

20.

Drapkin B, Farago A . Unexpected Synergy Reveals New Therapeutic Strategy in SCLC. Trends Pharmacol Sci. 2019; 40(5):295-297. DOI: 10.1016/j.tips.2019.03.005. View